Real-time enrollment status for this relapsed/refractory acute myeloid leukemia (r/r aml) clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 2:57 PM UTC
| NCT Number | NCT06786533 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) |
| Phase | Clinical Trial |
| Target Enrollment | 18 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Hemogenyx Pharmaceuticals LLC |
| Last Updated on CT.gov | August 14, 2025 (Aug 14, 2025) |
As of July 13, 2026: Clinical trial NCT06786533 is currently recruiting participants. This clinical trial study for relapsed/refractory acute myeloid leukemia (r/r aml) is actively seeking new participants at 1 location across the United States. The study is sponsored by Hemogenyx Pharmaceuticals LLC. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06786533 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06786533 was last updated Aug 14, 2025 (August 14, 2025). HelloStudys verifies this status automatically.